Nykode Therapeutics Future Growth
Future criteria checks 2/6
Nykode Therapeutics's earnings are forecast to decline at 21.2% per annum while its annual revenue is expected to grow at 24.2% per year. EPS is expected to decline by 12.3% per annum. Return on equity is forecast to be -77.1% in 3 years.
Key information
-21.2%
Earnings growth rate
-12.3%
EPS growth rate
| Biotechs earnings growth | 12.2% |
| Revenue growth rate | 24.2% |
| Future return on equity | -77.1% |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate
Aug 05
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?
Jan 25
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6 | -76 | -123 | -90 | 3 |
| 12/31/2025 | 17 | -53 | -57 | -63 | 4 |
| 12/31/2024 | 6 | -48 | -47 | -51 | 4 |
| 6/30/2024 | 7 | -38 | -88 | -87 | N/A |
| 3/31/2024 | 11 | -40 | -92 | -91 | N/A |
| 12/31/2023 | 13 | -35 | -99 | -97 | N/A |
| 9/30/2023 | 15 | -42 | -63 | -61 | N/A |
| 6/30/2023 | 13 | -47 | -57 | -55 | N/A |
| 3/31/2023 | 11 | -46 | -53 | -52 | N/A |
| 12/31/2022 | 9 | -43 | -23 | -21 | N/A |
| 9/30/2022 | 38 | -20 | 8 | 11 | N/A |
| 6/30/2022 | 38 | -12 | 11 | 14 | N/A |
| 3/31/2022 | 36 | -10 | 15 | 17 | N/A |
| 12/31/2021 | 36 | -9 | 0 | 1 | N/A |
| 9/30/2021 | 219 | 147 | 174 | 174 | N/A |
| 6/30/2021 | 218 | 146 | 174 | 174 | N/A |
| 3/31/2021 | 216 | 146 | 178 | 178 | N/A |
| 12/31/2020 | 216 | 150 | 180 | 180 | N/A |
| 9/30/2020 | 1 | -24 | -17 | -16 | N/A |
| 6/30/2020 | 1 | -19 | -14 | -14 | N/A |
| 3/31/2020 | 1 | -15 | -11 | -11 | N/A |
| 12/31/2019 | 1 | -14 | -11 | -10 | N/A |
| 9/30/2019 | 1 | -9 | -10 | -9 | N/A |
| 6/30/2019 | 1 | -9 | -9 | -9 | N/A |
| 3/31/2019 | 1 | -8 | -8 | -8 | N/A |
| 12/31/2018 | 1 | -7 | -7 | -7 | N/A |
| 9/30/2018 | 2 | -7 | N/A | N/A | N/A |
| 6/30/2018 | 1 | -5 | N/A | N/A | N/A |
| 3/31/2018 | 1 | -5 | N/A | N/A | N/A |
| 12/31/2017 | 1 | -4 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NYKD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NYKD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NYKD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NYKD's revenue (24.2% per year) is forecast to grow faster than the Norwegian market (2.2% per year).
High Growth Revenue: NYKD's revenue (24.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NYKD is forecast to be unprofitable in 3 years.